Rapid MRI and velocimetry of cylindrical Couette flow.

A narrow-gap, temperature-controlled Couette flow rheometer has been developed to study fluid velocities within the annular gap between two concentric cylinders by nuclear magnetic resonance (NMR) imaging and velocimetry. Alternative pulsed-field-gradient-based nuclear magnetic resonance imaging strategies which may be used for measurement of velocity within the Couette flow device have been evaluated. These include two-dimensional (2-D) imaging techniques with acquisition times of several minutes and a one-dimensional (1-D) projection method which exploits the symmetry of the device to reduce overall measurement time to less than 1 min. Velocity measurements made using each technique are presented for a Newtonian fluid undergoing Couette flow at shear rates of approximately 20 and 60 s(-1).

WIN 64821, a novel neurokinin antagonist produced by an Aspergillus sp. II. Biological activity.

WIN 64821, a secondary metabolite produced by Aspergillus sp. (ATCC 74177) was found to inhibit radiolabeled substance P (SP) binding in a variety of tissues, including those of human origin. This compound inhibited, in a competitive manner, the binding of SP with Ki values ranging from 0.24 microM in human astrocytoma U-373 MG cells to 7.89 microM in rat submaxillary membranes. Additionally, WIN 64821 was found to inhibit 125I-NKA binding to the NK2 receptor in human tissue at a concentration equivalent to its NK1 activity (0.26 microM). The inhibitory activity of WIN 64821 against an NK3 selective ligand, 3H-senktide, was found to be much weaker (Ki = 15.2 microM). WIN 64821 was also evaluated in NK1 functional assays and was found to be a competitive antagonist of SP-induced contractility in the guinea pig ileum (pA2 = 6.6) as well as an inhibitor of SP-induced 45Ca2+ efflux from human astrocytoma U-373 MG cells (IC50 = 0.6 microM). In a rat vas deferens model, WIN 64821 inhibited eledoisin-induced contractility with an IC50 of 3.4 microM indicating functional antagonism at the NK2 receptor. The data presented in this study provide biochemical, pharmacological and functional evidence supporting WIN 64821 as a competitive neurokinin antagonist.

Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids.

A binding assay for WIN 55212-2, an aminoalkylindole (AAI) with antinociceptive activity in rodents, is described. [3H]WIN 55212-2 bound to rat cerebellar membranes with a Kd of 2 nM and a maximum binding of 1.2 pmol/mg of protein. Specific binding in this filtration assay was greater than 90%, saturable, reversible, stereospecific, pH sensitive and heat labile. Binding was decreased by Na+, K+, Li+ and nonhydrolyzable analogs of GTP and increased by Mg++ and Ca++. The density of specific binding sites varied throughout the central nervous system with the highest found in the cerebellum, hippocampus and striatum and the lowest in the medulla/pons and spinal cord. The binding affinities of other AAIs for the WIN 55212-2 binding site correlated with their potencies for inhibiting neuronally stimulated contractions in the isolated mouse vas deferens. Of more than 60 compounds representing recognized neurotransmitter systems, only cannabinoids effectively inhibited binding. The effect of cannabinoids on AAI binding was consistent with competitive inhibition and suggests that AAI activity may be mediated in whole or in part by interaction with cannabinoid receptors. AAIs appear to represent a structurally novel class of compounds with which to study cannabinoid receptors.

Characterization of bradykinin B2 receptors on human IMR-90 lung fibroblasts: stimulation of 45Ca2+ efflux by D-Phe substituted bradykinin analogues.

[3H]Bradykinin binds to intact human IMR-90 fetal lung fibroblasts in a time and dose-dependent manner. Binding equilibrium was attained by 120 minutes at 4 degrees C. [3H]Bradykinin binding was saturable; Scatchard analysis of saturation binding data demonstrated a single binding site having a KD = 1.8 +/- 0.2 nM and a receptor concentration of 17.4 +/- 4.0 fmol/10(5) cells. The calculated value for KD(k-1/k1) from the association (k1 = 4.71 x 10(6) mol-1 min-1) and dissociation (k-1 = 1.13 x 10(-2) min-1) rate constants was 2.4 nM. The rank order of potency observed for bradykinin peptide agonists, bradykinin > Lys-bradykinin > Met,Lys-bradykinin > Ile,Ser-bradykinin >> des-Arg9-bradykinin, is consistent with that of a bradykinin B2 receptor. Bradykinin stimulated efflux of 45Ca2+ from IMR-90 cells dose dependently with an EC50 = 331 +/- 50 pM. 45Ca2+ efflux was also demonstrated with Lys-bradykinin and Met-Lys-bradykinin but not by des-Arg10-kallidin (100 nM) or NKA (1 microM). Hoe-140 inhibited bradykinin-induced 45Ca2+ efflux (IC50 = 3 +/- 2 nM). D-Phe7-substituted bradykinin analogues stimulated 45Ca2+ efflux dose dependently and this stimulation of 45Ca2+ efflux was inhibited by Hoe-140. These results suggest that D-Phe7 substituted bradykinin analogues are agonists at the bradykinin B2 receptor in IMR-90 cells.

Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles.

Extensive mapping of the cannabinoid receptor in rat brain has been reported recently using synthetic cannabinoids. Another class of compounds, the aminoalkylindoles (AAIs), does not resemble the cannabinoids structurally. Ligand binding data on isolated membranes, however, indicate that AAIs bind to the cannabinoid receptor. The present experiments compared the binding of AAIs and synthetic cannabinoids in vitro and by receptor autoradiography. The AAIs bound to a receptor in rat cerebellum with high affinity (Kd = 15 nM), and synthetic cannabinoids were potent competitors for AAI binding sites. In the autoradiographic studies in rat brain, an AAI and a synthetic cannabinoid were used to compete for the binding of a radiolabeled AAI to compare regionally and quantitatively the inhibition of AAI binding by the two classes of compounds. The distribution of the AAI binding was very similar to that reported for synthetic cannabinoid binding. These data add further evidence that the aminoalkylindoles bind to the cannabinoid receptor. Furthermore, the autoradiographic data for AAI binding, in addition to the autoradiographic data for the synthetic cannabinoid, provide a high degree of confidence in the localization of the cannabinoid receptor in the rat brain.

Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor.

Pravadoline (1) is an (aminoalkyl)indole analgesic agent which is an inhibitor of cyclooxygenase and, in contrast to other NSAIDs, inhibits neuronally stimulated contractions in mouse vas deferens (MVD) preparations (IC50 = 0.45 microM). A number of conformationally restrained heterocyclic analogues of pravadoline were synthesized in which the morpholinoethyl side chain was tethered to the indole nucleus. Restraining the morpholine diminished the ability of these pravadoline analogues to inhibit prostaglandin synthesis in vitro. In contrast, mouse vas deferens inhibitory activity was enhanced in [2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl] pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-(4-methoxyphenyl)methano ne (20). Only the R enantiomer of 20 was active (IC50 = 0.044 microM). An optimal orientation of the morpholine nitrogen for MVD inhibitory activity within the analogues studied was in the lower right quadrant, below the plane defined by the indole ring. A subseries of analogues of 20 and a radioligand of the most potent analogue, (R)-(+)-[2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo [1,2,3-de]-1,4-benzoxazin-6-yl](1-naphthalenyl)methanone (21) were prepared. Inhibition of radioligand binding in rat cerebellar membranes was observed to correlate with functional activity in mouse vas deferens preparations. Binding studies with this ligand (Win 55212-2) have helped demonstrate that the (aminoalkyl)indole binding site is functionally equivalent with the CP-55,940 cannabinoid binding site. These compounds represent a new class of cannabinoid receptor agonists.

Tyrosine hydroxylase in rat brain dopaminergic nerve terminals. Multiple-site phosphorylation in vivo and in synaptosomes.

Tyrosine hydroxylase, which catalyzes the initial step in catecholamine biosynthesis, is phosphorylated at serines 8, 19, 31, and 40 in intact pheochromocytoma (PC12) cells (Haycock, J.W. (1990) J. Biol. Chem. 265, 11682-11691). After 32Pi labeling of rat corpus striata in vivo or rat corpus striatal synaptosomes, 32P incorporation into tyrosine hydroxylase occurred predominantly at serines 19, 31, and 40. Electrical stimulation (30 Hz, 20 min) of the medial forebrain bundle (containing the afferent dopaminergic fibers) increased 32P incorporation into each of the three sites. Brief depolarization of the synaptosomes with elevated [K+]o (20-60 mM, 5-30 s) or veratridine (50 microM, 2 min) produced a selective increase in 32P incorporation into Ser19. Phorbol 12,13-dibutyrate (1 microM, 5 min) increased 32P incorporation into Ser31, and cAMP-acting agents such as forskolin (10 microM, 5 min) increased 32P incorporation into Ser40. In contrast, 32P incorporation into Ser8, which was usually detectable but very low, was not regulated either in vivo or in situ by any of the activators of signal transduction pathways. In synaptosomes, the only treatment found to increase Ser8 phosphorylation was okadaic acid (a protein phosphatase inhibitor), which increased 32P incorporation into all four phosphorylation sites. Thus, three different signal transduction systems appear to mediate the physiological regulation of tyrosine hydroxylase phosphorylation at three different sites.

A comparison of the new topical antibiotic mupirocin ('Bactroban') with oral antibiotics in the treatment of skin infections in general practice.

A trial was carried out in general practice in 200 patients presenting with skin infections to compare topical antibiotic treatment with mupirocin ointment with orally administered flucloxacillin or erythromycin. Patients were assigned at random to receive 4 to 10 days' treatment with either mupirocin applied 3-times daily or one of the oral antibiotics in the dosage normally used by the general practitioner for skin infections. The majority of infections were impetigo and infected wounds/lacerations; the main organisms isolated initially from 127 of the patients were either Staphylococcus aureus or beta-haemolytic Group A streptococci. Clinical response to mupirocin ointment (86% cured, 13% improved) was significantly better than that seen with erythromycin (47% cured, 26% improved) and similar to that with flucloxacillin (76% cured, 23% improved). Treatment outcome was not related to treatment duration with either the topical or oral preparations. Post-treatment samples from 76 patients showed that in the mupirocin group all the pathogens originally isolated were eliminated, including Gram-negative organisms.

Why do patients with lupus nephritis die?

Over 20 years 42 of 138 patients with systemic lupus erythematosus "died"--that is, suffered actual death or went into terminal renal failure, or both; data from 41 were available for analysis. In most patients the causes of death were multiple. Twenty seven patients went into terminal renal failure, of whom 25 were offered dialysis treatment. Three regained renal function later, 12 survived on dialysis or with functioning kidney allografts--almost all with inactive lupus--but 13 died after starting dialysis, most within a few weeks or months. The principal causes were active lupus or infection. In those patients with renal failure after rapid deterioration in renal function (n = 14) there were nine deaths, while of 10 patients with a slow evolution into renal failure, only four died. Four patients with impaired and 10 with normal renal function died, again most often from complications of lupus or from infection. Vascular disease was a major cause of death in seven patients, all but two of whom were young; of 15 postmortem examinations, eight showed severe coronary artery atheroma, and three surviving patients required coronary bypass operations. Analysis of the timing of death or entry into renal failure showed that in 12 out of 13 patients who died within two years of onset the lupus was judged to be active, while this was true in only eight out of 19 patients who died later. Six of the seven vascular deaths occurred later than two years from onset, while only nine of 26 renal "deaths" occurred before two years; deaths from infections (n = 13) were distributed equally. Despite this and aggressive treatment of active disease, the principal cause of actual death was uncontrolled lupus.

Differential effects of calcium on catecholamine synthesis regulation in olfactory tubercle and hypothalamic synaptosomes.

We have compared catecholamine synthesis regulation in rat brain olfactory tubercle and hypothalamic synaptosomes with regard to: calcium-dependency of stimulant drug-induced synthesis activation; tyrosine-dependency of amphetamine-induced synthesis stimulation, and the effects of the calcium chelator, ethylene glycol-bis-(beta-aminoethyl ether)N,N,N',N'-tetraacetic acid (EGTA). Amphetamine-induced synthesis stimulation was markedly calcium-dependent in the olfactory tubercle, but was completely calcium-independent in the hypothalamus. The effect of amphetamine on catecholamine synthesis in the olfactory tubercle was dependent upon the concentration of tyrosine in the incubation buffer; amphetamine produced a biphasic response, inhibiting synthesis at low tyrosine concentrations and activating synthesis at higher tyrosine concentrations. In contrast to the olfactory tubercle, amphetamine-induced stimulation of synthesis in the hypothalamus was observed at both low and high tyrosine concentrations. Distinct tissue differences in drug responsiveness were also observed following exposure to EGTA; synthesis was stimulated by EGTA in the olfactory tubercle but not in the hypothalamus. These data provide evidence for regional differences in catecholamine regulation in the brain, and suggest that some of these differences may be related to differential effects of calcium on catecholamine formation.

Dihydroxyphenylalanine production in rat brain striatal synaptosomes: stimulation by a calcium chelator.

By inhibiting aromatic L-amino-acid decarboxylase (EC 4.1.1.28) in rat brain striatal synaptosomes, we have been able to measure dihydroxyphenylalanine production via high performance liquid chromatography-electrochemical oxidation. This dihydroxyphenylalanine assay was compared to a standard radioisotopic assay of catecholamine synthesis (14CO2 production from L-[1-14C]tyrosine) in terms of (1) units of activity, (2) effects of known inhibitory and stimulatory agents, and (3) effects of the calcium chelator, EGTA. The units of activity in the dihydroxyphenylalanine assay were 40% greater than the units in the radioisotopic assay, indicating a mixing of labeled and endogenous tyrosine pools before conversion of the labeled tyrosine to labeled dihydroxyphenylalanine. The inhibition of synthesis produced by either 3-iodotyrosine or 3,4-dihydroxyphenylethylamine was similar in the two assays, as was the stimulation produced by 8-bromo cyclic AMP. The calcium chelator, EGTA, also activated synthesis to the same extent in the two assays, indicating that the increase observed in the radioisotopic assay is not an artifact of altered precursor specific activity. These data thus indicate the general utility of the synaptosomal dihydroxyphenylalanine synthesis assay, and also demonstrate the specific advantages of this assay for analyzing the effects of agents such as EGTA, which can alter tissue catecholamine precursor levels.

The stability of 6-hydroxydopamine under minipump conditions.

A number of investigators have recently used osmotic minipumps to continuously deliver the neurotoxin 6-hydroxydopamine (6-OHDA) to kitten cerebral cortex for periods up to 7 days. Because this compound is known to be particularly labile, we studied the stability of 6-OHDA stored under conditions similar to those found in an osmotic minipump. In 0.4% ascorbic acid, 4 mM 6-OHDA-HBr was found to be stable for at least one week as determined by (1) assay of the drug by high performance liquid chromatography and electrochemical detection and (2) test of the drug's ability to deplete mouse heart norepinephrine.

Chromatographic and histochemical identification of dopamine within an identified neuron in the leech nervous system.

Each segmental ganglion of the leech nervous system has two pairs of lateral roots extending to the body wall and viscera. A cluster of about eight neuron cell bodies is located proximal to the first major branch of each anterior root and is termed the anterior root ganglion (ARG). Only one of these eight cells is vitally-stained by Neutral Red dye and fluoresces an intense blue-green following the glyoxylic acid histochemical condensation. The emission spectrum of this anterior root cell (AR) is stable under continuous UV illumination and is bimodal, with peaks at about 480 and 515 nm. This spectrum is indistinguishable from that of millimolar solutions of dopamine (DA) in gelatin droplets following glyoxylic acid histochemistry. We utilized high performance liquid chromatography and an amperometric detector to measure DA within the AR neurosomata at 1.01 pmol/cell. The AR cells in this study had an average diameter of 23 micron and therefore, the minimum intrasomatal concentration of DA is 160 mM, an unusually high level for any neurotransmitter. We measured DA in anterior axons at 0.83 pmol, in segmental ganglia at 1.07 pmol, and in longitudinal connectives at 0.16 pmol. Control neurosomata (Retzius cells) and axonal tracts which lack blue-green fluorescence (posterior and distal anterior roots), had no detectable DA (less than 0.06 pmol/sample). These data establish that the catecholamine DA is responsible for the fluorescence of the AR cell.